Previous Page
Moreover, HEADWATERS has repurchased and canceled $5.0 million in aggregate principal amount of its 2.50% Convertible Subordinated Notes due 2014 for consideration of approximately $4.7 million, including accrued interest through the purchase date of approximately $0.05 million, pursuant to an open market transaction. After the closing of the note purchase, Headwaters has $58.6 million in aggregate principal amount of its 2.50% Notes remaining.
Heidelberg Instruments announced order for an advanced DWL 2000 system with sophisticated Gray Scale Exposure capability from Heptagon. The System will be used for production of micro optical components for applications in smart phones, mobile devices, gaming consoles, telecoms equipment and supercomputers.
HelioVolt announced successful completion of testing of the next series of high efficiency thin film solar modules. HelioVolt now offers a range of solar panels based on the company’s proprietary CIGS (Copper Indium Gallium Selenide) technology platform. The new series of high performance modules features HelioVolt’s frameless glass-glass construction and monolithic integration offering customers outstanding energy yield, cost, and reliability.
"Our unique technology and manufacturing capabilities allow HelioVolt to continue to rapidly expand our product portfolio. We are also pleased that our panels offer industry leading narrow power distributions to deliver higher system performance to our customers," said Dr. BJ Stanbery, HelioVolt’s founder and Chairman of the Board.
IBM (NYSE: IBM) has entered into a definitive agreement to acquire Texas Memory Systems (TMS), a leading developer of high-performance flash memory solutions. TMS is a privately held company based in Houston, Texas. Financial terms of the deal were not disclosed.
llumina (NASDAQ: ILMN) launched its real-time PCR reagent portfolio, including a novel, probe-based chemistry for gene expression analysis called NuP- CRTM. In addition to the NuPCR Reagents, Illumina announced qPCR DNA Binding Dye (DBD) Assays for Gene Expression Analysis and qPCR High Resolution Melting (HRM) Assays for genotyping studies, providing researchers with a trio of high-quality, budget-friendly options in the qPCR reagent market. Moreover, Illumina announced its financial results for the second quarter of 2012. Revenue decrease 2% to $281 million ($287m in 2Q 2011); GAAP net income for the quarter was $23 million, or $0.18 per diluted share, compared to net income of $31 million, or $0.22 per diluted share, for the second quarter of 2011. The cash flow from operations was $96 million compared to cash flow from operations